Loading company…
NEOsphere develops small-molecule degraders and uses proteomics to identify therapeutic targets.
Founded in Planegg, Germany, in 2022 by Henrik Daub and Jutta Fritz, NEOsphere Biotechnologies develops small-molecule degraders for therapeutic use. Its proteomics platform screens potential targets and degrader chemistries to support drug development. In August 2022, it raised EUR 6 million in Series A funding led by Ventura BioMed Investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in